Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2021 11:05 ET | Source: Bragar Eagel & Squire

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc and Encourages Investors to Contact the Firm

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against...
October 03, 2021 10:00 ET | Source: The Rosen Law Firm PA

FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM

NEW YORK, Oct. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
September 23, 2021 16:48 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Iterum Therapeutics plc Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
September 06, 2021 06:12 ET | Source: The Rosen Law Firm PA

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Iterum Therapeutics plc Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM

NEW YORK, Sept. 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
August 30, 2021 17:00 ET | Source: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Iterum Therapeutics plc Investors With Losses Over $100K to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
May 14, 2020 06:45 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Reports First Quarter 2020 Financial Results

--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
March 31, 2020 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
March 12, 2020 06:45 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
February 19, 2020 07:30 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
December 26, 2019 17:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection

DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...

Next Page keyboard_arrow_right